QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers
Latest Information Update: 14 May 2026
At a glance
- Drugs YE-NEO-001 (Primary)
- Indications HER2 negative breast cancer; HER2 positive breast cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms QUILT-2.025 NANT
- Sponsors NantBioScience
Most Recent Events
- 07 May 2026 Actual Primary Completion Date is 18 Mar 2025.
- 07 May 2026 Status changed from active, no longer recruiting to completed.
- 22 Jun 2023 Planned End Date changed from 30 Dec 2020 to 30 Dec 2025.